{"name":"AvenCell Europe GmbH","slug":"avencell-europe-gmbh","ticker":"","exchange":"","domain":"avencelleuropegmbh.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi_wJBVV95cUxQdjJacHczR2gzM2FTc0ZCcTI5eDRNSlhUbmZRRUx4YVdzZGZNcGx0b2xHc19oZkROdkhUWXFoMEY2bmxmSVNjSFZPZFdkVlQ5aHJLeWlzYXlnOFdIN1BzbDhhLXBXVUFDem01NTJYR2hpODEyb1FKS2hucmdxdlRvXzBieU14cm91SVlOS2NacVFSZVJZTC0yN1EtVVl5R2tXOEhhVjB3cElxeDVWSzdlRzUtZWVsXzZCMEJ6aTN0aFNxbHlFY1NZN0s3c3VndWlKNFpMVE9OTWVSQ0I0LXZFbDlTbFBCczRBNWdQMk9oYU5vZS11X2QzYXMtdVlwR1o2VzI1QjhjTEg2Tms4dUN0VFV4NmYzNDVpSFFyTTNtclJ2aW5mTm9WeVVQWk9DdW1JUVpiM0t3eXNORVZRRkt5RmVjTnYtem9uV21NejVqcm5TTkdfR1pkVVVpcXdWSHBBVjc5c3c2UHBiOWt0eTJpV25ObVRvSXVxYWRWcF9Gbw?oc=5","date":"2026-04-02","type":"trial","source":"BioSpace","summary":"AvenCell Therapeutics Announces First Patient Dosed in Phase I QUADvance Study with AVC-203, a Novel Allogeneic CD19/CD20 Dual-Targeting CAR-T Investigational Therapy for the Treatment of Relapsed/Ref","headline":"AvenCell Therapeutics Announces First Patient Dosed in Phase I QUADvance Study with AVC-203, a Novel Allogeneic CD19/CD2","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-04","type":"regulatory","source":"PR Newswire","summary":"AvenCell Therapeutics Announces IND Clearance and EMA Approval of Clinical Trial Application (CTA) for the QUADvance Study, a Phase I/II trial evaluating AVC-203, a Novel Allogeneic CD19/CD20 CAR-T In","headline":"AvenCell Therapeutics Announces IND Clearance and EMA Approval of Clinical Trial Application (CTA) for the QUADvance Stu","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxOdG5HU0kwZUNwSWpYcl8wQmNEMGg1a2gya0lRN1c5SDFfWDUtZzU0ZTdtUEw2TXI2YzRpMG91NHJuYW9rZF9TUldVaHR1MU5GUkdndDF2THo1SHhna1RXXzJ1UVN2VWdqX1kxeU52dmlQeGJrd3QwZmktV3NYa3pzcjVBSTMtNGNPZU9YdHZyUXJnaFYxdlFtRElHazdzem5KMVZwY3F1WkRCMEd5eTE2b2NFNXZTMHhPT2dzc2pkLVNaYTBEdnF2OFJVbXpGM0d2eDVwSXhYMUxXcVEtT2IzaG9aYWZHLXkz?oc=5","date":"2025-01-06","type":"regulatory","source":"CRISPR Medicine News","summary":"Press Release Service: CAR-T Cell Therapy Market Research 2024-2025: Size, Forecasts, Trials, and Trends - Approved CAR-T Therapies and Late-stage Clinical Trials that Could Reach Commercialization So","headline":"Press Release Service: CAR-T Cell Therapy Market Research 2024-2025: Size, Forecasts, Trials, and Trends - Approved CAR-","sentiment":"positive"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}